Enhanced Therapeutic Potential of Adoptive Immunotherapy by In Vitro CD28/4-1BB Costimulation of Tumor-Reactive T Cells Against a Poorly Immunogenic, Major Histocompatibility Complex Class I-Negative A9P Melanoma
Scott E. Strome(Northwestern Medicine Lake Forest Hospital), Lieping Chen(Yale Cancer Center), Beth A. Martin(Mayo Clinic), Daniel J. Sargent(National Institute of Agricultural Botany), Dallas B. Flies(Mayo Clinic in Arizona), Andrei I. Chapoval(Human Genome Sciences (United States)), Suyu Shu(Cleveland Clinic), Koji Tamada(Yamaguchi University)
Cited by 39
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
|Nature Medicine|2002|5.1k
Tumor Microsatellite-Instability Status as a Predictor of Benefit from Fluorouracil-Based Adjuvant Chemotherapy for Colon Cancer
|New England Journal of Medicine|2003|2.1k
Anti–PD-1/PD-L1 therapy of human cancer: past, present, and future
|Journal of Clinical Investigation|2015|1.4k
B7-H3: A costimulatory molecule for T cell activation and IFN-γ production
|Nature Immunology|2001|1k